FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567182779> ?p ?o ?g. }

• W1567182779 endingPage "145" @default.
• W1567182779 startingPage "139" @default.
• W1567182779 abstract "Aims: To investigate if the International Prostate Symptom Score (IPSS) voiding-to-storage subscore ratio (IPSS-V/S) can help to guide the treatment for male lower urinary tract symptoms (LUTS). Methods: Men aged 40 years or older with a total IPSS (IPSS-T) 8 or more were constitutively enrolled from January 2010 to December 2010. The IPSS voiding (IPSS-V) and storage subscore (IPSS-S) were recorded separately, and the IPSS-V/S was calculated. Patients were divided into two groups according to the baseline IPSS-V/S value. First-line doxazosin (4 mg per day) and tolterodine (4 mg per day) monotherapy were given to patients with IPSS-V/S > 1 and IPSS-V/S ≤ 1, respectively. The IPSS-T, IPSS-V, IPSS-S, quality of life (QoL), maximum flow rate (Qmax), voided volume and postvoid residual (PVR) were measured at 1 month (visit 1) and 3 months (visit 2) after treatment. Results: After medical treatment for 1 month, 89/116 (76.7%) patients receiving tolterodine and 218/279 (78.1%) patients receiving doxazosin reported an improved outcome (global response assessment, GRA ≥ 1 point). The mean IPSS-T, IPSS-S decreased, and QoL improved significantly in both groups. Significant increased Qmax, voided volume, decreased IPSS-V and PVR were noted only in patients receiving doxazosin. There was no significant increase of PVR (from 50.1 to 60.4 ml, p = 0.106), and no patient developed urinary retention after tolterodinie monotherapy for 1 month. However, patients aged more than 70 years had significant association with increased PVR (≥ 50 ml). Conclusion: Initial treatment with doxazosin for patients with IPSS-V/S > 1 and tolterodine for patients with IPSS-V/S ≤ 1 is safe and feasible. Elderly people (≥ 70 years) and patients with Qmax < 10 ml/s are more likely to have increased PVR (≥ 50 ml)." @default.
• W1567182779 created "2016-06-24" @default.
• W1567182779 creator A5029982064 @default.
• W1567182779 creator A5031644679 @default.
• W1567182779 creator A5035247872 @default.
• W1567182779 creator A5053694613 @default.
• W1567182779 date "2012-01-19" @default.
• W1567182779 modified "2023-10-17" @default.
• W1567182779 title "Therapeutic effect of α-blockers and antimuscarinics in male lower urinary tract symptoms based on the International Prostate Symptom Score subscore ratio" @default.
• W1567182779 cites W1567909777 @default.
• W1567182779 cites W1696237278 @default.
• W1567182779 cites W1962053352 @default.
• W1567182779 cites W1967312126 @default.
• W1567182779 cites W1978424391 @default.
• W1567182779 cites W1992243709 @default.
• W1567182779 cites W2005687876 @default.
• W1567182779 cites W2012618608 @default.
• W1567182779 cites W2018142772 @default.
• W1567182779 cites W2022805390 @default.
• W1567182779 cites W2024922462 @default.
• W1567182779 cites W2053732828 @default.
• W1567182779 cites W2073337601 @default.
• W1567182779 cites W2078160609 @default.
• W1567182779 cites W2078997630 @default.
• W1567182779 cites W2088552272 @default.
• W1567182779 cites W2089437227 @default.
• W1567182779 cites W2095401957 @default.
• W1567182779 cites W2106355635 @default.
• W1567182779 cites W2134121470 @default.
• W1567182779 cites W2136535014 @default.
• W1567182779 cites W2146458227 @default.
• W1567182779 cites W2993539218 @default.
• W1567182779 cites W4249807744 @default.
• W1567182779 doi "https://doi.org/10.1111/j.1742-1241.2011.02864.x" @default.
• W1567182779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22257039" @default.
• W1567182779 hasPublicationYear "2012" @default.
• W1567182779 type Work @default.
• W1567182779 sameAs 1567182779 @default.
• W1567182779 citedByCount "21" @default.
• W1567182779 countsByYear W15671827792012 @default.
• W1567182779 countsByYear W15671827792013 @default.
• W1567182779 countsByYear W15671827792014 @default.
• W1567182779 countsByYear W15671827792015 @default.
• W1567182779 countsByYear W15671827792016 @default.
• W1567182779 countsByYear W15671827792017 @default.
• W1567182779 countsByYear W15671827792018 @default.
• W1567182779 countsByYear W15671827792020 @default.
• W1567182779 crossrefType "journal-article" @default.
• W1567182779 hasAuthorship W1567182779A5029982064 @default.
• W1567182779 hasAuthorship W1567182779A5031644679 @default.
• W1567182779 hasAuthorship W1567182779A5035247872 @default.
• W1567182779 hasAuthorship W1567182779A5053694613 @default.
• W1567182779 hasConcept C121608353 @default.
• W1567182779 hasConcept C126322002 @default.
• W1567182779 hasConcept C126894567 @default.
• W1567182779 hasConcept C142724271 @default.
• W1567182779 hasConcept C159110408 @default.
• W1567182779 hasConcept C204787440 @default.
• W1567182779 hasConcept C2776235491 @default.
• W1567182779 hasConcept C2776547966 @default.
• W1567182779 hasConcept C2777590997 @default.
• W1567182779 hasConcept C2778941218 @default.
• W1567182779 hasConcept C2779478474 @default.
• W1567182779 hasConcept C2779951463 @default.
• W1567182779 hasConcept C2781020410 @default.
• W1567182779 hasConcept C71924100 @default.
• W1567182779 hasConcept C84393581 @default.
• W1567182779 hasConceptScore W1567182779C121608353 @default.
• W1567182779 hasConceptScore W1567182779C126322002 @default.
• W1567182779 hasConceptScore W1567182779C126894567 @default.
• W1567182779 hasConceptScore W1567182779C142724271 @default.
• W1567182779 hasConceptScore W1567182779C159110408 @default.
• W1567182779 hasConceptScore W1567182779C204787440 @default.
• W1567182779 hasConceptScore W1567182779C2776235491 @default.
• W1567182779 hasConceptScore W1567182779C2776547966 @default.
• W1567182779 hasConceptScore W1567182779C2777590997 @default.
• W1567182779 hasConceptScore W1567182779C2778941218 @default.
• W1567182779 hasConceptScore W1567182779C2779478474 @default.
• W1567182779 hasConceptScore W1567182779C2779951463 @default.
• W1567182779 hasConceptScore W1567182779C2781020410 @default.
• W1567182779 hasConceptScore W1567182779C71924100 @default.
• W1567182779 hasConceptScore W1567182779C84393581 @default.
• W1567182779 hasIssue "2" @default.
• W1567182779 hasLocation W15671827791 @default.
• W1567182779 hasLocation W15671827792 @default.
• W1567182779 hasOpenAccess W1567182779 @default.
• W1567182779 hasPrimaryLocation W15671827791 @default.
• W1567182779 hasRelatedWork W1567182779 @default.
• W1567182779 hasRelatedWork W1982398919 @default.
• W1567182779 hasRelatedWork W2066550653 @default.
• W1567182779 hasRelatedWork W2067551626 @default.
• W1567182779 hasRelatedWork W2328530680 @default.
• W1567182779 hasRelatedWork W2349755398 @default.
• W1567182779 hasRelatedWork W2419093920 @default.
• W1567182779 hasRelatedWork W2795398985 @default.
• W1567182779 hasRelatedWork W4205205601 @default.
• W1567182779 hasRelatedWork W1772230244 @default.
• W1567182779 hasVolume "66" @default.

• next